Paul Blanchfield: Anthony, I’m going to start by — I’ll speak to what our expectations are from a share perspective. The share is a fixed pool, it’s 100%. So the only thing you know for sure is that any participants have to share that number. What we’re really confident about is that we will remain a demanding leader in this marketplace from a market share perspective. For this quarter, we were reporting approximately 70% is our estimated share. And again, I need to be clear about that because there is no — unlike the pharmaceutical industry, there is no third-party here that explicitly and very carefully follow and track market share. So we do have to estimate it. But our estimate is, again, 70% of the market, and we continue to be the market leader, and we will continue to be the market leader, which is a really great place to be.
And your Europe question, it’s not one that we will answer specifically this time, although I really appreciate your comments about the infrastructure of PMS being less, but yet the incidence and prevalence for gentlemen prostate cancer being higher. What I will say is, we’re really confident with our partner, Curium, is the leading PMS provider. They have the largest network of PMS throughout Europe. And so that’s, as you know, from our launch, that’s an important, important access point that really once you have the infrastructure, then you can drive the demand. But it will be our partner doing that, so it would be really early in probably, I would say, inappropriate this time for us to offer any projections there.
Operator: Thank you. One moment for your next question. And for your next question is come from the line of Justin Walsh from Jones Trading. Just your line is now open.
Justin Walsh: LNTH1363S is still early, but I was wondering if you can comment on the potential advantages and disadvantages of copper 64 pet compared with fluorine 18 pet imaging. And sort of related to that, why use copper for targeting fat and flooring for PSMA? And is there some concern that the future entrance of copper-based PSMA agents could pressure clarify down the road? Thanks.
Mary Anne Heino: I’m going to comment to your question generally, and then we can absolutely jump deeper into the science on, but I think what you’re seeing here for the larger marketplace is the intent to deploy a variety of isotopes and then exploit, what are the individual differences between the different 64 is a really good into for pet. It has a short positron range, which is just a little bit longer than F18 and the longer half-life. So remember, with the positron range, that’s where you get clarity of image. So it has — it’s a little bit longer than that they see but not noticeably. So you get that nice clear image. But with a longer half-life really distinct commercial advantages about how to distribute your product.
And so I will say copper production has a long way to go in terms of scale-up. Cerium is the only company that we’re aware with a commercial copper 64 products in the U.S., which is close to that’s an orphan indication. So the overall value moving that’s available that is probably lower. But again, I would point you to what we’re seeing in the larger marketplace. And this goes to some of the outputs as well as some of the other isotopes. The intent within radiopharmaceuticals to employ and deploy these isotopes across a variety of imaging and therapeutic products that really make for me, as I said earlier, my really personalized medicine. And so that’s kind of our stance. I won’t do a direct comparison at 18 comp other than what I just talked to you about the positron range and then the half-life.
But really, you always have to think about the full product. What is the isotopes. What is the ligand or other being plated or conjugated and look at the total value being offered by that product.
Operator: All right. Thank you. And for your next question comes from the line of Larry Solow from CJS. Larry, your line is open. Please ask your question.
Larry Solow: Great. Good morning. Just a clarification first and then a question. So your guidance essentially is on 45, 570 to $574 584, right? — apples for apples, including real store.
